Drug Information

Drug General Information
Drug ID
D0DI8J
Former ID
DIB011554
Drug Name
BMS-275183
Synonyms
BMS-198246; Oral taxane (cancer), BMS; Oral taxane (cancer), Bristol-Myers Squibb
Drug Type
Small molecular drug
Indication Cancer [ICD9: 140-229; ICD10:C00-C96] Phase 2 [521864]
Company
Bristol-Myers Squibb Co
Structure
Download
2D MOL

3D MOL
Formula
C43H59NO16
Canonical SMILES
CC(C)([C@@H]([C@H](C(=O)O[C@@H]1C(=C2[C@@H](OC(=O)C)C(=<br />O)[C@]3([C@H]([C@@H]([C@](C1)(C2(C)C)O)OC(=O)c1ccccc1)[<br />C@]1([C@@H](C[C@@H]3O)OC1)OC(=O)OC)C)C)O)NC(=O)OC(C)(C)<br />C)C
PubChem Compound ID
6918594
Target and Pathway
Target(s) Tubulin Target Info Inhibitor [531077]
References
Ref 521864ClinicalTrials.gov (NCT00359450) Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer). U.S. National Institutes of Health.
Ref 531077A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies. Invest New Drugs. 2011 Dec;29(6):1426-31.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.